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Several recent pharmacogenetic studies have investigated the variability in both outcome
and toxicity in cisplatin-based therapies. These studies have focused on the genetic
variability of therapeutic targets that could affect cisplatin response and toxicity in diverse
type of cancer including lung, gastric, ovarian, testicular, and esophageal cancer. In this
review, we seek to update the reader in this area of investigation, focusing primarily on
DNA reparation enzymes and cisplatin metabolism through Glutathione S-Transferases
(GSTs). Current evidence indicates a potential application of pharmacogenetics in
therapeutic schemes in which cisplatin is the cornerstone of these treatments. Therefore,
a collaborative effort is required to study these molecular characteristics in order to
generate a genetic panel with clinical utility.
Keywords: pharmacogenetics, chemotherapy, cisplatin, polymorphisms, NER pathway, glutathione S-transferases
INTRODUCTION
Cisplatin is an alkylating agent used to treat several types of
cancers that works by causing DNA lesions via the forma-
tion of intrastrand and interstrand crosslinks, resulting in the
activation of various signal-transduction pathways that block
cellular processes, such as replication and transcription. The
action of cisplatin is cell cycle-independent, although in some
cases, prolonged G2 phase cell-cycle arrest occurs (Siddik, 2003;
Kelland, 2007). Cisplatin has a central role in cancer chemother-
apy for testicular, ovarian/cervical, head and neck, and non-
small-cell cancers. The side effects include nephrotoxicity (Wong
and Giandomenico, 1999), hematogenesis and neurotoxicity
(Decatris et al., 2004).
From the beginning, cisplatin has presented variations in
therapeutic response. While some tumors are hypersensitive to
anticancer therapy, other tumors have an intrinsic resistance.
Investigations have sought an explanation of this variation and
have suggested that the major resistance mechanisms include
reduction in drug levels that reach the target DNA due to reduced
uptake and/or increased efflux; increased cellular thiol levels;
enhanced DNA repair and/or increased damage tolerance; and
failure of cell-death pathways after the formation of platinum-
DNA adducts (Fojo, 2001; Siddik, 2003; Wang and Lippard,
2005). In each of these processes there exist potential sites of phar-
macogenetics variability (Figure 1). Changes at the genetic level
causing modifications in cellular phenotype could explain some
of the variability in response and toxicity to cisplatin-included
chemotherapy. In this review, we discuss associations between
genetic variants in the germ line and in outcomes following
cisplatin-based chemotherapy. We mainly focus on DNA repair
and cisplatin detoxification through Glutathione S-Transferases
(GSTs).
PHARMACODYNAMIC MECHANISMS
Cisplatin modulates several signal transduction pathways involv-
ing AKT (v-akt murine thymoma viral oncogene homolog),
c-ABL (v-abl Abelson murine leukemia viral oncogene homolog
1), p53, and MAPK (mitogen-activated protein kinase)/JNK (c-
Jun NH2-terminal kinase)/ERK (extracellular signal-regulated
kinase). Cell death induced by cisplatin is concentration depen-
dent and includes necrosis and apoptosis mechanisms (Gonzalez
et al., 2001). Necrosis involves hyper-activation of Poly (ADP
ribose) polymerase (PARP) (Nguewa et al., 2003) while apopto-
sis results from activation of CASP8, CASP9, CASP3, and CASP7
(Gonzalez et al., 2001).
Cisplatin distorts the structure of the DNA that gener-
ate intrastrand 1, 2—crosslinks binding proteins into shal-
low minor groove [high-mobility group (HMG) box proteins,
repair proteins, transcription factors, histone H1] (Kartalou and
Essigmann, 2001; Wozniak and Blasiak, 2002; Zdraveski et al.,
2002). It covalently binds DNA and forms DNA adducts through
intra- and interstrand crosslinks (ICLs). Intrastrand crosslinks
are repaired by nucleotide excision repair (NER) using the other
strand as a template. As both strands are compromised in ICLs,
other enzymes are involved in their repair. Two major pathways
of ICL repair exist; one is replication dependent and mainly
involves homologous recombination, the second is replication
independent and involves NER (Ho and Schärer, 2010). At the
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FIGURE 1 | Potential sources of variability to clinical response to
cisplatin treatment. Abbreviations: DNA, deoxyribonucleic acid; GSTs,
glutathione S-Transferases; NER, nucleotide excision repair; LPR2, Low
Phosphate Root2; SLC31A1 (CTR1), solute carrier family 31 (copper
transporter), member 1; SLC22A2, solute carrier family 22 (organic
cation transporter), member 2; ERCCs, Excision Repair Cross
Complementing group of proteins; XPC, Xeroderma Pigmentosum
Group C Protein.
start of both of these pathways, translesion (TLS) polymerases
are needed to bypass ICLs and restore one of the two DNA
strands. Translesion synthesis is a mechanism used by cells to
prevent common DNA damage from stalling replication forks
and rising apoptosis levels. The most important TLS polymerases
are Pol ζ (Polymerase zeta) and REV1 (Reversionless 1). Studies
have shown that disruption or suppression of expression of both
REV3L, the gene encoding the catalytic subunit of Pol ζ, or
REV1 modifies sensitivity to cisplatin (Lin et al., 2006; Doles
et al., 2010). Goricar et al. (2014) recently determined in patients
with malignant mesothelioma that the mutant allele in REV1
rs3087403 and REV1 TGT haplotype associated with increased
risk for leukopenia and neutropenia. REV3L rs465646, rs462779,
and REV3L CCGG haplotype associated with longer overall sur-
vival (Goricar et al., 2014).
DNA REPAIR ENZYMES
DNA damage repair mechanisms are as follows: direct repair of
alkyl adducts; repair of base damage and single strand breaks
by base excision repair; repair of double strand breaks by
homologous recombination or by non-homologous end joining;
repair of bulky DNA adducts by NER; and repair of mismatches
and insertion/deletion loops by DNA mismatch repair (Camps
et al., 2007). The NER pathway is one of the major DNA repair
systems involved in the removal of platinum adducts. This path-
way involves many proteins in lesion recognition, excision, DNA
synthesis and ligation. Excision repair cross-complementary 1
(ERCC1) is a key protein involved in the process of NER and
ERCC1-xeroderma pigmentosum (ERCC1-XPF) catalyzes inci-
sion on the incision 50 side to the site of DNA damage (Parker
et al., 1991; Bessho, 1995). In addition to ERCC1, xeroderma
pigmentosum complementary group D (XPD) encodes a heli-
case that participates in both NER and basal transcription as
part of the transcription factor, IIH. Mutations destroying the
enzymatic function of XPD protein are manifested clinically in
combinations of three severe syndromes, including xeroderma
pigmentosum, XP combined with Cockayne Syndrome and tri-
chothiodystrophy (Lehmann, 2001; Clarkson and Wood, 2005).
ERCC1 and ERCC2 (XPD) have pivotal roles in the NER path-
way, this has been evidenced in studies where lower levels of
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intratumoral ERCC1 mRNA are significantly correlated with
improved survival due to enhanced tumor cell sensitivity to
cisplatin (Shirota et al., 2001). mRNA levels as well as the over-
expression of ERCC1 and other enzymes have been implicated in
the development of clinical resistance to platinum (Kirschner and
Melton, 2010; Cheng et al., 2012).
Among these genes, the most studied is ERCC1 gene, mostly
focused on the therapy of non-small cell lung cancer (NSCLC)
and esophageal cancer. Polymorphisms in ERCC1 include mainly
rs3212986 and rs11615. The polymorphism rs3212986 is located
in the 3′ untranslated region and therefore may affect mRNA sta-
bility resulting in a decreased expression levels (Chen et al., 2000).
In relation to rs3212986, the C allele leads to a change that results
in an increase in overall survival (Zhou et al., 2004; Krivak et al.,
2008; Takenaka et al., 2010), progression free survival (Krivak
et al., 2008; Kim et al., 2009; Ercˇulj et al., 2012; Chen et al., 2013),
treatment response (Li et al., 2010) and prognosis (Takenaka
et al., 2010; Okuda et al., 2011). However, opposite associations
have been reported in other studies related to reduced responses
with the C allele (Bradbury et al., 2009; Kalikaki et al., 2009;
Park et al., 2011; Wang et al., 2011), as well as increased tox-
icity (Khrunin et al., 2010; Tzvetkov et al., 2011; Ercˇulj et al.,
2012). Wang et al. (2011) and Bradbury et al. (2009) showed
that in esophageal cancer, patients with A/A or A/C genotype
had improved outcomes compared with patients carrying wild-
type genotypes. In addition, Park et al. (2011) have found similar
results in metastatic cancer patients. On the contrary, opposite
results have been found in NSCLC and ovarian cancer where
the C allele relates to improved survival and treatment response.
The variability in outcomes amongst these studies could be due
to tumor characteristics (tissue-specific or organ-specific). The
polymorphism C→T at codon 118 located on exon 4 of ERCC1
gene (rs11615) is expected to have the same effect. This poly-
morphism is associated with clinical response to platinum-based
chemotherapy inNSCLC. The C allele is also related to an increase
in overall survival (Isla et al., 2004; Ryu et al., 2004; Cheng et al.,
2012; Joerger et al., 2012), progression free survival (Ryu et al.,
2004; Cheng et al., 2012; Joerger et al., 2012), improved treat-
ment response (Kalikaki et al., 2009) and prognosis (Okuda et al.,
2011). Nevertheless, others authors detect opposite associations
in larger-population studies, including amongst Chinese patients
(Li et al., 2010; Ren et al., 2012): this should be considered in
future research. Nephrotoxicity has been related to the C allele
in rs3212986 ERCC1 (Tzvetkov et al., 2011), T allele in rs11615
ERCC1 (Tzvetkov et al., 2011) and C/T genotype in rs3212986
ERCC1 (Khrunin et al., 2010), independent of cancer type.
Another widely studied gene is ERCC2 (XPD). The pres-
ence of a variation in ERCC2 gene (rs13181 and rs1799793)
reduces repair capacity, and results in greater efficacy of cis-
platin treatment due to increased DNA damage and an enhanced
cytotoxic effect. rs1799793 generates a positive effect in overall
survival and progression free survival (Gurubhagavatula et al.,
2004; Bradbury et al., 2009; Biason et al., 2012). Ercˇulj et al.
(2012) found that G/G genotype is related to an increase in var-
ious types of toxicity (Ercˇulj et al., 2012) while nephrotoxicity
has been shown by Joerger et al. (2012) (Joerger et al., 2012).
The A allele in the mutation rs13181 increases overall survival
(Park et al., 2001; Quintela-Fandino et al., 2006; Caronia et al.,
2009; Chew et al., 2009). However, other authors have found the C
allele related to increased overall survival (Bradbury et al., 2009)
in esophageal cancer and progression free survival in pancreatic
cancer (Avan et al., 2013). These discrepancies suggest that asso-
ciations with C allele are not fully clear in these types of cancers,
and that patients factors, treatment modalities and ethnic popu-
lation could influence the outcome. Nonetheless, the majority of
the results support an association between both rs1799793 and
rs13181 and clinical outcomes in patients with NSCLC, osteosar-
coma, breast cancer, ovarian cancer, and colorectal cancer. These
significant associations in ERCC2 polymorphisms and clinical
outcomes have included studies with a larger number of patients
and differing patient populations.
Other studies found associations between ERCC5 mutations
(rs1047768 and rs751402), PFS (progression free survival) (Sun
et al., 2013) and OS (overall survival) (He et al., 2013). These
studies have indicated that ERCC5 polymorphisms are involved
in the efficacy of cisplatin neoadjuvant chemotherapy. Also, oto-
toxicity has related to rs2228001 mutation in the Xeroderma
Pigmentosum Complementation group C (XPC) gene (Caronia
et al., 2009). More information is needed about these associations
to reach more powerful conclusions, including a greater number
of patients and amongst different ethnic populations.
Additional DNA repair genes have also shown variability,
including X-ray repair cross-complementing group 1 (XRCC1).
This protein is involved in base excision repair. Among the
mutations, we highlight rs25487 and rs1799782 mutations. In
relation to rs25487, the mutant G variant has been associated
with decreased treatment response (Gurubhagavatula et al., 2004;
Giachino et al., 2007; Pacetti et al., 2009; Khrunin et al., 2010;
Joerger et al., 2012; Ke et al., 2012; Miao et al., 2012), although
opposite results exist (Quintela-Fandino et al., 2006; Sakano et al.,
2006). Other evidence indicates associations between the G allele
and neutropenia (Khrunin et al., 2010). T allele in rs1799782
mutation is related with an increase (Miao et al., 2012; Li and Li,
2013) and decrease in overall survival (Li et al., 2006; Shim et al.,
2010). Li and Li (2013) and Miao et al. (2012) have performed
studies in ovarian cancer with a large number of patients. Further
data are required to confirm this association. Another finding is
the relation between treatment response and the T allele (Wang
et al., 2004; Yuan et al., 2006; Kim et al., 2009; Ke et al., 2012).
This discrepancy may be due to cancer type or combined thera-
pies. DNA repair enzymes might decrease the synergistic effects
of combination of cisplatin and radiation and information from
population should be added in future association specifics to sub-
groups (Li and Li, 2013). In addition, some studies have used
cisplatin in combination with paclitaxel, gemcitabine, cyclophos-
phamide or 5-FU, depending on cancer type. Others factors that
might affect variability in different populations are the stage of
disease, patient status and period of follow-up in survival analysis.
With respect to X-ray repair cross complementing protein 3
(XRCC3), a protein involved in DNA double-strand breaks, the
rs861539 mutation is the only one that relates to treatment out-
come. Increased overall survival was associated with the T allele
(De las Peñas et al., 2006; Chen et al., 2012) as was progression
free survival (Font et al., 2008). However, Ren et al. (2012) have
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shown inverse results (Ren et al., 2012) including a large num-
ber of patient (n = 340) with NSCLC. More data are necessary to
confirm these opposing results.
In summary, studies of association between genetic variants in
the DNA repair system and clinical results show that these vari-
ants can be potential biomarkers for outcomes in the cisplatin-
based therapies (Table 1). Despite race and treatment regimen,
associations testing the polymorphism in ERCC1 appear to follow
a consistent direction. rs3212986 and rs11615 polymorphisms
should be considered in a future genetic panel because results
were obtained in several researches with different treatment and
demographic characteristics. Additional research should be per-
formed in order to replicate results found with polymorphisms
in ERCC2, XRCC1, and XRCC3. In additional studies, the later
polymorphism should be used to evaluate clinical outcomes
(overall survival and disease progression) considering different
subgroups of patient. In relation to specific toxicities, associations
with nephrotoxicity have been described and characterized, but
likewise require confirmation.
PHARMACOKINETIC MECHANISMS
Evidence indicates that reduced drug accumulation is a signifi-
cant mechanism of cisplatin resistance (Kelland, 1993). The cause
may be an inhibition in drug uptake, an increase in drug efflux, or
both. Studies concerning the mechanisms of cisplatin uptake into
the cell have focused on both passive diffusion (Hromas et al.,
1987; Binks and Dobrota, 1990; Mann et al., 1991) and copper
transporters (Katano et al., 2002; Ohashi et al., 2003; Safaei et al.,
2004).
Recent studies have demonstrated that mutation or deletion of
the CTR1 gene results in increased cisplatin resistance and reduc-
tion of platinum levels (Ishida et al., 2002). Copper-transporting
P-type adenosine triphosphate (ATP7B) is associated with cis-
platin resistance in vitro (Komatsu et al., 2000), and in various
cancers (Nakayama et al., 2002, 2004; Ohbu et al., 2003). ATP-
binding cassette sub-family C2 (ABCC2), another transporter
protein, also has a role in cisplatin resistance, probably promot-
ing drug efflux (Koike et al., 1997; Kool et al., 1997; Cui et al.,
1999). ABCC3 is a member of the multidrug resistance protein
(MRP) family. Caronia et al. (2011) found that rs4148416 was
associated with low survival. In addition, the ABCB1 gene that is
well-known and encodes P-glycoprotein, contains three polymor-
phisms (rs2032582, rs1045642, and rs1128503) that have been
studied individually and as a haplotype, however, the results have
been inconsistent (Caronia et al., 2011).
DETOXIFICATION
Cisplatin is inactivated by conjugation with glutathione through
the GSTs. This phase II enzyme catalyzes the conjugation of reac-
tive metabolites with negatively charged hydrophilic molecules
for disposal in excretion processes. Genetic variations in GSTs
have been implicated in cellular resistance to cancer chemother-
apy and in outcomes of cisplatin-based treatments. When GSTs
enzymes with reduced activity are present, the available concen-
tration in the drug in tumor tissue increases. In these patients
therapy might be more effective, but might also be severely toxic
(Strange et al., 2000; Siddik, 2003; Quiñones et al., 2006). Several
studies have shown significant association between polymorphic
GSTs genes and cisplatin treatment response suggesting these
polymorphisms as potential biomarkers (Table 2).
In the GSTs superfamily there are eight cytosolic classes
(Alpha, kappa, mu, omega, pi, sigma, theta, and zeta) (Katoh
et al., 2008; Luo et al., 2011). GSTP1, GSTM1, and GSTT1 genes,
have been the most widely studied in relation to the functional
polymorphisms. GSTP1 is widely expressed in normal human
epithelial tissues. A single nucleotide substitution (A→G) at posi-
tion 313 (rs1695) of the GSTP1 gene, results in replacement of
isoleucine with valine at codon 105 of the enzyme, substantially
diminishes GSTP1 enzyme activity. On the contrary, GSTM1 and
GSTP1 genetically delected (homozygous null allele) will lead to
an absence of enzymatic activity (Stoehlmacher et al., 2002).
The GSTP1 gene has been the most studied in a wide num-
ber of cancers with controversial results related to cisplatin-
based therapy. Some investigations have shown that patients with
G/G genotype present less toxicity (Oldenburg et al., 2007a,b;
Goekkurt et al., 2009; Kim et al., 2009) with more survival
(Goekkurt et al., 2006; Ruzzo et al., 2006; Ji et al., 2013) and better
therapy response (Sun et al., 2010; Yang et al., 2012). On the other
hand, the G allele has been associated with a risk of myelosuppres-
sion, polyneuropathy, and toxicity (Yokomizo et al., 2007; Joerger
et al., 2012; Windsor et al., 2012; Rednam et al., 2013). In ovar-
ian cancer, the A allele is related to better PFS and OS (Khrunin
et al., 2010). GSTP1 A/A genotype has been found to predict sub-
optimal response to flurouracil/cisplatin chemotherapy and poor
survival in patients with advanced gastric cancer (Ruzzo et al.,
2006). The influence of rs1695 GSTP1 on toxicity to taxane-and
platinum-based chemotherapy is in debate (Kim et al., 2009).
Polymorphism of GSTM1 and GSTT1 genes is associated
with cisplatin-based treatments.GSTM1 null has been specifically
related to an increase of OS and PFS (Medeiros et al., 2003; Petros
et al., 2005; Beeghly et al., 2006; Ott et al., 2008). Concerning tox-
icity, it has been associated with a decrease in toxicity (Oldenburg
et al., 2007a,b; Khrunin et al., 2010), although Dhawan et al.
(2013) showed the opposite but with a small sample (n = 23)
(Dhawan et al., 2013). On the GSTT1 gene, the non-null allele
relates to an increase in overall survival and progression free sur-
vival (Goekkurt et al., 2009), however, Kim et al. (2009) showed
the opposite but this contradiction apparently is caused by differ-
ent definitions of patient response. Moreover, the null allele has
also associated with an increase in ototoxicity (Jurajda et al., 2012;
Choeyprasert et al., 2013). Finally, additional studies examining
the GSTA1 gene showed the T/T genotype (rs3957357) asso-
ciates with an increase of overall survival (Khrunin et al., 2010).
Regarding to GSTM3 gene, the AGG/AGG haplotype (rs1799735)
is related to less thrombocytopenia, anemia and neuropathy
(Khrunin et al., 2010). Nevertheless, more evidence is needed in
order to determine a clear role of GSTA1 and GSTM3 genes on
cisplatin-based therapy.
Polymorphisms in the GSTP1 gene have shown controversial
results among different types of cancer. Some studies found the
polymorphic allele related to less toxicity, better therapy response
and more survival but others found the opposite regarding to
toxicity (Rednam et al., 2013). The results obtained by several
authors demonstrate that the GSTM1 null allele is consistently
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related to overall survival in different types of cancer. Concerning
toxicity, few investigation have found associations, therefore the
role of this polymorphism on toxicity is not clear. On the other
hand, theGSTT1 null allele associates with toxicity in patients car-
rying this polymorphism. Regarding OS and PFS it appears that
null allele is related to decreased OS and PFS, although one author
showed the opposite (Ruzzo et al., 2006; Goekkurt et al., 2009).
This contradiction apparently is caused by different definitions of
patient response.
Together, the evidence appears to indicate a strong association
between GSTs polymorphisms and clinical response (overall sur-
vival and disease progression). However, the effects on toxicity
do not appear to have a clear and dominant trend, and may be
related to differing treatment modalities in each of the studies.
Despite this, with the data presented we can conclude that the
GSTP1 polymorphic allele and the GSTM1 and GSTT1 null alle-
les appear to result in enhanced overall survival and progression
free survival, particularly in gastric cancer where the data have
been more consistent. Lack of activity in GSTs enzymes appear to
lead to a better treatment response.
CONCLUSION
Personalized therapy promises improved outcomes to treat-
ment with respect to efficacy and toxicity of treatment. Ideally,
sub-groups of patients that would require adjustment to ther-
apy based on genetic information could be detected prior
to commencing treatment, and therapy accordingly optimized.
Pharmacogenetics, the study of the role of inheritance in indi-
vidual variation in drug response, can address cisplatin cellular
resistance, providing tools to achieve the modification of cur-
rent treatments in different types of cancer, including lung, gas-
tric, ovarian, testicular and, esophageal cancers (Weinshilboum,
2003).
Variable responses to different treatments, including cisplatin,
have been seen from different points of view. When looking into
the genetic variability in processes where cisplatin is involved,
including pharmacokinetics and pharmacodynamics, efforts have
delivered evidence regarding DNA repair systems andmetaboliza-
tion systems. Within the variability in DNA repair processes, key
genes involved include ERCC1, ERCC2 (XPD), ERCC5, XRCC1,
XRCC3, and XPC genes. Studies examining the genetic variability
of cisplatin metabolism have shown that the main genes involved
areGSTP1,GSTM3,GSTM1, andGSTT1. Currently there appears
to be a group of genes that would influence variability in response
and toxicity in cisplatin-based therapies which we present here in
this up-dated review.
Diverse results have been found among the polymorphisms
analyzed in both DNA repair enzymes and detoxification
enzymes. These contradictions and variations are primarily due
to the heterogeneity amongst studies (patient population, treat-
ment and number of subjects). Another possibility is with
the inclusion of a large number of candidate genes, there is
always a risk of false positive associations. For example, recent
studies showed a relationship between rs12201199 in thiop-
urine S-methyltransferase gene (TPMT) and rs9332377 in the
catechol-O-methyltransferase gene (COMPT) with cisplatin-
induced hearing loss in children (Ross et al., 2009). Our opinion
is that future studies in this line should include the genes we have
highlighted, and that a collaborative effort is required to improve
the quality and strength of evidence in order to achieve a validated
panel of polymorphisms that guides therapeutic decisions.
Finally, prospective clinical studies employing polymorphism
panels in these treatment procedures are required to determine
whether adjustment of therapy based on genetic information can
influence outcomes in these scenarios.
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